-+ 0.00%
-+ 0.00%
-+ 0.00%

The 2026 European Society of Medical Oncology Annual Meeting will be held in Madrid, Spain from October 23 to 27, local time. Meanwhile, the Phase III Horizon-Breast06 study on HER2-ADC recontrastuzumab independently developed by Hengrui Pharmaceutical to treat advanced breast cancer with low HER2 expression was published. The full study was simultaneously published in the top journal “Journal of the American Medical Association”. The study confirmed that both those not receiving advanced chemotherapy or the entire population showed statistically significant and clinically significant prolongation of PFS.

Zhitongcaijing·10/24/2026 09:01:00
Listen to the news
The 2026 European Society of Medical Oncology Annual Meeting will be held in Madrid, Spain from October 23 to 27, local time. Meanwhile, the Phase III Horizon-Breast06 study on HER2-ADC recontrastuzumab independently developed by Hengrui Pharmaceutical to treat advanced breast cancer with low HER2 expression was published. The full study was simultaneously published in the top journal “Journal of the American Medical Association”. The study confirmed that both those not receiving advanced chemotherapy or the entire population showed statistically significant and clinically significant prolongation of PFS.